Business Description
UroGen Pharma Ltd
NAICS : 325412
SIC : 2834
ISIN : IL0011407140
Description
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.48 | |||||
| Equity-to-Asset | -0.22 | |||||
| Debt-to-Equity | -2.37 | |||||
| Debt-to-EBITDA | -1.13 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.87 | |||||
| Beneish M-Score | -1.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 1313.1 | |||||
| 3-Year EBITDA Growth Rate | 6.6 | |||||
| 3-Year EPS without NRI Growth Rate | 7.4 | |||||
| 3-Year FCF Growth Rate | -3.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 33.7 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.15 | |||||
| 9-Day RSI | 64.08 | |||||
| 14-Day RSI | 58.75 | |||||
| 6-1 Month Momentum % | 18.79 | |||||
| 12-1 Month Momentum % | 37.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.06 | |||||
| Quick Ratio | 6.87 | |||||
| Cash Ratio | 5.72 | |||||
| Days Inventory | 192.65 | |||||
| Days Sales Outstanding | 59.49 | |||||
| Days Payable | 185.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.2 | |||||
| Shareholder Yield % | -10.39 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 87.92 | |||||
| Operating Margin % | -92.15 | |||||
| Net Margin % | -136 | |||||
| FCF Margin % | -110.36 | |||||
| ROA % | -78.9 | |||||
| ROIC % | -254.28 | |||||
| ROC (Joel Greenblatt) % | -887.65 | |||||
| ROCE % | -82.51 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.38 | |||||
| EV-to-EBIT | -3.99 | |||||
| EV-to-EBITDA | -4.06 | |||||
| EV-to-Revenue | 4.64 | |||||
| EV-to-Forward-Revenue | 3.44 | |||||
| EV-to-FCF | -4.15 | |||||
| Earnings Yield (Greenblatt) % | -25.06 | |||||
| FCF Yield % | -20.73 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:URGN
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
UroGen Pharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 77.275 | ||
| EPS (TTM) ($) | -4.23 | ||
| Beta | 0.81 | ||
| Volatility % | 123.56 | ||
| 14-Day RSI | 58.75 | ||
| 14-Day ATR ($) | 0.685188 | ||
| 20-Day SMA ($) | 12.2015 | ||
| 12-1 Month Momentum % | 37.9 | ||
| 52-Week Range ($) | 7.15 - 24.13 | ||
| Shares Outstanding (Mil) | 30.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
UroGen Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
UroGen Pharma Ltd Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
UroGen Pharma Ltd Frequently Asked Questions
What is UroGen Pharma Ltd(URGN)'s stock price today?
The current price of URGN is $13.31. The 52 week high of URGN is $24.13 and 52 week low is $7.15.
When is next earnings date of UroGen Pharma Ltd(URGN)?
The next earnings date of UroGen Pharma Ltd(URGN) is 2024-03-15 Est..
Does UroGen Pharma Ltd(URGN) pay dividends? If so, how much?
UroGen Pharma Ltd(URGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers